Prosecution Insights
Last updated: April 19, 2026
Application No. 18/009,126

USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS V

Non-Final OA §112§DP
Filed
Dec 08, 2022
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
824 granted / 1014 resolved
+21.3% vs TC avg
Moderate +9% lift
Without
With
+8.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
56 currently pending
Career history
1070
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
20.9%
-19.1% vs TC avg
§112
41.9%
+1.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1014 resolved cases

Office Action

§112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of formula I in which examined variables X and Y are each limited to a direct bond and variable Z is a phenyl ring in the reply filed on 2026 January 27 is acknowledged. The traversal is on the ground(s) that there is a common core in newly amended claim 1. This is found persuasive because the common core is phenyl-ethynylene-C(R4)=N-O-methylene-phenylene-CH[C(O)-R1 -Me][R2-OMe]. Claims 1-9, 11, 12, and 14 are allowable except for the presence of grainy images. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement, as set forth in the Office action mailed on 2025 October 2, is hereby withdrawn and claims 1-9, 11, 12, and 14 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Priority Applicant has filed a certified copy of EPO 21176864.3, 2021 May 31. The filing receipt says the priority is based on EPO 21276864.3. Certified Copy PNG media_image1.png 156 484 media_image1.png Greyscale Filing Receipt PNG media_image2.png 38 352 media_image2.png Greyscale Specification The disclosure is objected to because of the following informalities: Multiple compounds of Table S in the specification are difficult to read. In compounds 51-128, it is hard to tell if an O is connected to a nitrogen of an oxime group. Additionally the substituents attached to left-hand side terminal ring are grainy quality or should be large enough to read without straining one’s eyes. Present Image PNG media_image3.png 72 222 media_image3.png Greyscale Higher Quality Image PNG media_image4.png 299 733 media_image4.png Greyscale Appropriate correction is required. Claim Objections Claims 1-9, 11, 12, and 14 are objected to because of the following informalities: the displayed image of formula I is grainy and difficult to read. It is hard to tell if there is a bond between variable R2 and a carbon atom. If the image looked like the following, the image would be legible. Present Image PNG media_image5.png 80 258 media_image5.png Greyscale Higher Quality Image PNG media_image6.png 341 779 media_image6.png Greyscale Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 8 and 9 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In both of these claims, examined variables X and Y have the same meaning as they do in in claim 1, a direct bond. Therefore neither of these claims are further limiting with respect to claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 4-9, 11, 12, and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, and 4-13, of copending Application No. 19 / 124203 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because compound 8 (specification page 114) meets the limitations of the following examined variables: Ra is F; R4 is CH2OCH3; R3 is Br; R1 is O; and R2 is CH. PNG media_image7.png 120 546 media_image7.png Greyscale This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Allowable Subject Matter Claims 1-9, 11, and 14 are not allowable. The following is a statement of reasons for the indication of allowable subject matter: KULKARNI (EP 3945089, published 2022 February 2) describes example 1 (page 41, line 41 to page 42, line 43). This compound does not anticipate or render obvious a compound of claim 1 because the reference was published 2022 February 2, after the effective filing date of the examined application, 2020 July 31. PNG media_image8.png 188 682 media_image8.png Greyscale Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Dec 08, 2022
Application Filed
Feb 17, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595235
PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES
2y 5m to grant Granted Apr 07, 2026
Patent 12595265
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12588410
ORGANIC ELECTROLUMINESCENT MATERIAL AND METHOD PREPARING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12570660
PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE
2y 5m to grant Granted Mar 10, 2026
Patent 12570626
DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+8.7%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 1014 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month